Lea B. Witkowsky

Lea B. Witkowsky

Auto-generated profile, based on publicly available information

Lea B. Witkowsky

Kavli Center for Ethics, Science, and the Public, University of California, Berkeley, Berkeley, CA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2021 in medRxiv
Verified
Preprint
Open access
PDF file
AEAlexander J. Ehrenberg
Alexander J. Ehrenberg
EMErica A. Moehle
Erica A. Moehle
CBCara E. Brook
Cara E. Brook
ACAndrew H. Doudna Cate
Andrew H. Doudna Cate
LWLea B. Witkowsky
Lea B. Witkowsky
JDJennifer A. Doudna
Jennifer A. Doudna
Summary: Regular surveillance testing of asymptomatic individuals for SARS-CoV-2 has played a vital role in SARS-CoV-2 outbreak prevention on college and university campuses. Here we describe the voluntary saliva testing program instituted at the University of California, Berkeley during an early period of the SARS-CoV-2 pandemic in 2020. The program was administered as a research study ahead of clinical implementation, enabling us to launch surveillance testing while continuing to optimize the assay. Results of both the testing protocol itself and the study participants’ experience show how the program succeeded in providing routine, robust testing capable of contributing to outbreak prevention within a campus community and offer strategies for encouraging participation and a sense of civic responsibility.

29 December 2025 in Blood Advances
Verified
Journal Article
Open access
WWWilliam Wood
William Wood
OYOsman N. Yogurtcu
Osman N. Yogurtcu
ESEmily Semmel
Emily Semmel
KHKathleen Hewitt
Kathleen Hewitt
DNDonna S. Neuberg
Donna S. Neuberg
GPGregory Pappas
Gregory Pappas
Real-world evidence (RWE) has been used to improve quality of care, accelerate innovation, and evaluate emerging therapies for drugs, devices, and biologics. The Coordinated Registry Network (CRN), aggregating and linking highly curated patient data, has emerged as a model for RWE generation that has guided the development of the American Society of Hematology Research Collaborative (ASH RC) Data Hub. With the aim of bolstering research, enhancing clinical care, and expediting evidence generation using RWE, the ASH RC and the Innovative Genomics Institute launched a joint initiative, “Accelerating Innovations for Sickle Cell Disease (SCD) with Real-World Evidence,” to evaluate and make recommendations to the Data Hub. An expert panel used a "maturity model" to evaluate the following: (1) Data Hub standardization of RWE guidelines to ensure successful monitoring of new therapies' safety and effectiveness; and (2) the Data Hub’s engagement with patients (including collection of data on patient experience) and collaboration among partners, including regulators, industry, and clinicians. The Data Hub gathers patient-level data from electronic health records, with plans to incorporate data from individuals receiving gene therapy. The program is currently curating and aggregating data on ∼27 000 individuals with SCD cared for across 22 hospitals in the United States. The SCD Data Hub program includes a total of 56 centers, some of which are not yet contributing data, which will increase the total cohort to ∼50 000 patients. The unique organizational structure of the CRN model facilitates acceleration of innovation through collaborative relationships between multiple clinical sites and partners with various evidentiary needs.